Pcn76 - Budget Impact Analysis of Afatinib for the First-Line Treatment of Advanced or Metastatic Non–small-Cell Lung Cancer in China

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.158
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Analysis of Continuous First‑line Treatment With Docetaxel and Carboplatin for Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2014English

Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2019English

Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Immunotherapy
OncologyAllergyImmunology
2019English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy